AXSM - Axsome Therapeutics, Inc.
| Previous Close | 24.85 |
| Open | 25.10 |
| Bid | 24.80 x 900 |
| Ask | 24.84 x 3200 |
| Day's Range | 24.58 - 25.36 |
| 52 Week Range | 1.94 - 28.00 |
| Volume | 107,126 |
| Avg. Volume | 1,241,688 |
| Market Cap | 840.959M |
| Beta (3Y Monthly) | 2.86 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.28 |
| Earnings Date | Aug 6, 2019 - Aug 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 35.00 |
- Motley Fool•6 days ago
About to Buy Penny Stocks? Look at These 3 Companies First
Investors seeking stocks with high reward potential might want to consider this pharmaceutical company, oil and gas driller, and wind blade maker instead of wading into the high-risk penny stock market.
- Zacks•10 days ago
Implied Volatility Surging for Axsome (AXSM) Stock Options
Investors need to pay close attention to Axsome (AXSM) stock based on the movements in the options market lately.
- Motley Fool•10 days ago
5 Best Biotech Stocks of 2019 So Far
These biotech stocks have at least quadrupled in just over six months this year.
- Motley Fool•15 days ago
Here's Why Axsome Therapeutics Stock Rocketed 813% in the First Half of 2019
This tiny biotech is racing toward a blockbuster drug launch.
- Benzinga•20 days ago
The Daily Biotech Pulse: Celyad To Advance Leukemia Drug To Clinical Trial, Positive Data For Teva's Migraine Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 1) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Arena Pharmaceuticals, ...
- GlobeNewswire•21 days ago
Axsome Therapeutics Added to Russell 3000® and Russell 2000® Indexes
Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, has been added to the Russell 3000® and Russell 2000® Indexes, as part of the annual Russell indexes reconstitution, which took place following the US market close on June 28, 2019. The Russell indexes are rebalanced each June in order to capture growing equities and market changes that occurred in the preceding year. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
- Insider Monkey•26 days ago
Hedge Funds Have Never Been This Bullish On Axsome Therapeutics, Inc. (AXSM)
Hedge funds and other investment firms that we track manage billions of dollars of their wealthy clients' money, and needless to say, they are painstakingly thorough when analyzing where to invest this money, as their own wealth also depends on it. Regardless of the various methods used by elite investors like David Tepper and David […]
- Zacks•27 days ago
Axsome Initiates Phase III Study on Depression Candidate
Axsome (AXSM) initiates phase III GEMINI study of AXS-05 for the treatment of major depressive disorder.
- GlobeNewswire•28 days ago
Axsome Therapeutics Initiates GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder
Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, enrolled the first patient in its GEMINI (Glutamatergic and Monoaminergic Modulation in Depression) study, a Phase 3, randomized, double-blind, placebo-controlled trial of AXS-05 in the treatment of major depressive disorder (MDD). AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity.
- Motley Fool•last month
3 Stocks the World's Best Investors Are Buying Right Now
Big-time investors have been buying shares of this small-cap biotech, e-commerce giant, and Canadian utility.
- GlobeNewswire•last month
Axsome Therapeutics Provides Update on Continued Progress at Annual Stockholders’ Meeting
Placebo-controlled Phase 3 trial of AXS-05 in MDD on track to start in 2Q 2019 Topline results from both STRIDE-1 Phase 3 trial in TRD and planned placebo-controlled Phase 3.
- Simply Wall St.•2 months ago
Do Institutions Own Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares?
A look at the shareholders of Axsome Therapeutics, Inc. (NASDAQ:AXSM) can tell us which group is most powerful...
- Motley Fool•2 months ago
3 Top Small-Cap Stocks to Buy in June
Don't miss out on these small-cap bargains.
- GlobeNewswire•2 months ago
Axsome Therapeutics To Present Data From ASCEND Phase 2 Trial Of AXS-05 In Major Depressive Disorder At The 2019 American Society For Clinical Psychopharmacology Annual Meeting
NEW YORK, May 21, 2019 -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous.
- Motley Fool•2 months ago
These 3 Small-Cap Healthcare Stocks Reported Big Updates This Month
Axsome Therapeutics, Flexion Therapeutics, and UroGen Pharma gave investors reasons for excitement.
- Motley Fool•2 months ago
Here's Why You'll Regret Ignoring This Biotech Stock Rocket
This startup has rapidly developed two potential blockbusters that are close to the finish line, and hardly anybody's noticed yet.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of AXSM earnings conference call or presentation 9-May-19 12:00pm GMT
Q1 2019 Axsome Therapeutics Inc Earnings Call
Motley Fool•2 months agoAxsome Therapeutics, Inc. (AXSM) Q1 2019 Earnings Call Transcript
AXSM earnings call for the period ending March 31, 2019.
- Associated Press•2 months ago
Axsome: 1Q Earnings Snapshot
On a per-share basis, the New York-based company said it had a loss of 32 cents. Axsome shares have increased sixfold since the beginning of the year. The stock has risen fivefold in the last 12 months. ...
- GlobeNewswire•2 months ago
Axsome Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update
Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the first quarter ended March 31, 2019. “The first five months of 2019 have been highly productive at Axsome as we advanced our mission to develop innovative medicines for patients living with serious and difficult-to-treat CNS disorders. “We also received Breakthrough Therapy designation from the FDA for AXS-05 for the treatment of major depressive disorder, and recently announced, based on the Breakthrough Therapy meeting, an expedited clinical development plan for AXS-05 in depression which could result in a potential NDA filing for AXS-05 in 2020.
- MarketWatch•2 months ago
Harry Boxer’s four stocks to watch include cybersecurity company Carbon Black
Axsome Therapeutics Inc. (AXSM) gained 39 cents to $19.54 on Tuesday on 1.4 million shares traded. The biotech company announced Monday that the FDA granted breakthrough therapy designation for a major depressive disorder treatment. It’s now right at lateral resistance, a break through which could lead to the $20 range short-term.
- Benzinga•2 months ago
4 Stocks Breaking Out On Earnings & Other News
Here are four stocks to watch with strong technical momentum fueled by earnings and other news. Axsome Therapeutics, Inc. (NASDAQ: AXSM ) gained 39 cents to $19.54 on Tuesday on 1.4 million shares. The ...
- Motley Fool•2 months ago
Small-Cap Stocks to Watch in May
These two companies are set to announce important business updates this month.
- Zacks•2 months ago
What's in the Cards for Fuel Tech (FTEK) in Q1 Earnings?
Fuel Tech's (FTEK) Q1 results are likely to benefit from increased adoption of emission control solutions, efforts to improve sales channel and addition of a coal-fired unit in the United States.
- Zacks•2 months ago
What's in Store for Axsome (AXSM) This Earnings Season?
On Axsome's (AXSM) first-quarter earnings call, investors will look for its progress with the CNS pipeline candidates and the regulatory updates on the same.
